

# Evidence for the use of triage, respiratory isolation, and effective treatment to reduce the transmission of *Mycobacterium tuberculosis* in health care settings: a systematic review

Aaron S Karat<sup>1</sup>, Meghann Gregg<sup>2</sup>, Hannah E Barton<sup>3</sup>, Maria Calderon<sup>4</sup>, Jayne Ellis<sup>5</sup>, Jane Falconer<sup>6</sup>, Indira Govender<sup>1</sup>, Rebecca C Harris<sup>1</sup>, Mpho Tlali<sup>7</sup>, David AJ Moore<sup>1</sup>, Katherine L Fielding<sup>1</sup>

## Affiliations

- 1 TB Centre, London School of Hygiene & Tropical Medicine, London, United Kingdom
- 2 Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, United Kingdom
- 3 University College Hospital, University College London Hospitals NHS Foundation Trust, London, United Kingdom
- 4 Universidad Peruana Cayetano Heredia, Lima, Peru
- 5 Hospital for Tropical Diseases, University College London Hospitals NHS Foundation Trust, London, United Kingdom
6. Library & Archives Service, London School of Hygiene & Tropical Medicine, London, United Kingdom
7. Centre for Infectious Disease Epidemiology and Research (CIDER), School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa

## Corresponding author

Dr Aaron Karat, Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT  
Email: [aaron.karat@lshtm.ac.uk](mailto:aaron.karat@lshtm.ac.uk) | ORCID: 0000-0001-9643-664X

## Alternate corresponding author

Professor Katherine Fielding, Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, Keppel Street London WC1E 7HT  
Email: [katherine.fielding@lshtm.ac.uk](mailto:katherine.fielding@lshtm.ac.uk) | ORCID: 0000-0002-6524-3754

## Key points

25 articles were found. Most studies showed reduced LTBI or TB disease incidence after implementation of an intervention package, but evidence was weak for effectiveness of individual interventions. We make recommendations for future research to provide a better evidence base.

## 32 **Abstract**

---

33 Evidence is limited for infection prevention and control (IPC) measures reducing *Mycobacterium tuberculosis*  
34 (MTB) transmission in health facilities. This systematic review, one of seven commissioned by the World  
35 Health Organization to inform the 2019 update of global tuberculosis (TB) IPC guidelines, asked: do triage  
36 and/or isolation and/or effective treatment of TB disease reduce MTB transmission in health care settings?

37 Of 25 included articles, 19 reported latent TB infection (LTBI) incidence in health care workers (HCWs;  
38 absolute risk reductions 1%–21%); five reported TB disease incidence in HCWs (no/slight [high TB burden] or  
39 moderate [low burden] reduction) and two in HIV-positive in-patients (6%–29% reduction). 23/25 studies  
40 implemented multiple IPC measures; effects of individual measures could not be disaggregated.

41 Packages of IPC measures appeared to reduce MTB transmission, but evidence for effectiveness of triage,  
42 isolation, or effective treatment, alone or in combination, was indirect and low quality. Harmonising study  
43 designs and reporting frameworks will permit formal data syntheses and facilitate policymaking.

44

## 45 **Introduction**

---

46 Tuberculosis (TB) is the leading infectious cause of death worldwide.<sup>1,2</sup> Health care workers (HCWs) are at  
47 higher risk of TB than the general population, likely because of exposure in health facilities.<sup>3-7</sup> Infection  
48 prevention and control (IPC) measures to reduce *Mycobacterium tuberculosis* (MTB) transmission in health  
49 care settings are considered under three categories: environmental controls (e.g., mechanical ventilation);  
50 personal protection (e.g., using respirators); and administrative controls (e.g., coordinating efforts between  
51 governmental health departments).<sup>8</sup> Evidence is limited, however, for the effectiveness of individual IPC  
52 measures in reducing MTB transmission, and guidelines have been written based heavily on expert opinion.<sup>9-</sup>  
53 <sup>11</sup>

54 This systematic review was one of seven complementary reviews commissioned by the World Health  
55 Organization (WHO) to inform the update of the 2009 TB IPC guidelines.<sup>12</sup> It aimed to answer the question:  
56 do 1) triage of people with TB signs, symptoms or with confirmed TB disease; and/or 2) respiratory isolation  
57 of presumed or demonstrated infectious TB cases; and/or 3) effective treatment of TB disease reduce the  
58 transmission of MTB to HCWs or other populations (including patients and visitors) in health care settings,  
59 when compared with transmission to the same populations in settings without, or with different, IPC  
60 interventions? The primary findings of this review were presented to the WHO guideline development group  
61 (GDG) and collated in an online appendix to the 2019 guidelines.<sup>13</sup> The guidelines contain recommendations  
62 for practice based on consideration of a wide range of evidence and should be the primary resource for  
63 implementation; this article looks more closely at how these interventions have been studied and discusses  
64 the implications for future TB IPC research.

## 65 **Methods**

---

66 The review protocol was registered on 12 February 2018 on the International Prospective Register of  
67 Systematic Reviews (ref. CRD42018085226).<sup>14</sup> Countries were classified as high or low TB burden based on  
68 WHO lists published in 2016.<sup>15</sup>

69 **Population, interventions, comparators, and outcomes**

70 Populations of interest were HCWs and non-HCWs working in/attending health care settings with applied  
71 intervention/s. Interventions of interest, specified by the WHO GDG, were: (1) triage based on signs,  
72 symptoms, or diagnosis of TB; (2) respiratory isolation (or spatial separation); and (3) effective treatment of  
73 TB based on bacteriologic susceptibility. WHO commissioned separate reviews to examine the use of  
74 environmental and personal protective measures.<sup>13</sup> Comparators used were HCWs and non-HCWs working  
75 in/attending health care settings with no or different intervention/s. Outcomes of interest were differences  
76 in LTBI or TB disease incidence/prevalence or measures of relative difference in incidence/prevalence  
77 (Appendix 1).

78 **Search strategy, terms, and sources**

79 Search strategies were constructed and run by an experienced professional librarian (final search 30  
80 November 2017). Details of search terms and sources are provided in Supplementary tables 1 and 2.

81 **Selection of studies and inclusion and exclusion criteria**

82 Sifting (using criteria in Table 1) and data extraction were conducted in duplicate by two reviewers, with  
83 unresolved disagreements resolved by a third, independent reviewer, who also checked included articles.  
84 Citation tracking was conducted in Web of Science and/or Scopus® (details in Appendix 1). Systematic  
85 reviews meeting the inclusion criteria were used to find additional articles describing primary research and  
86 were not themselves included in the analysis.

87 **Data management and assessment of risk of bias**

88 Data management procedures are described in Appendix 1. Bias assessments were conducted at study level  
89 (using the Cochrane tool for experimental and prospective cohort studies [[http://www.cochrane-](http://www.cochrane-handbook.org)  
90 [handbook.org](http://www.cochrane-handbook.org)] and Downs & Black for other observational studies)<sup>16</sup> and at outcome level for Grading of  
91 Recommendations Assessment, Development and Evaluation (GRADE;<sup>17,18</sup> using scales for before/after  
92 studies<sup>19</sup> and cross-sectional studies [adapted Newcastle-Ottawa]).

## 93 **Data analysis**

94 Due to the heterogeneity of the data, study designs, and populations studied, meta-analysis could not be  
95 conducted. Findings were synthesised using a narrative approach, with studies organised in line with key  
96 outcomes of interest pre-specified by WHO.<sup>14</sup>

## 97 **Results**

---

98 The search yielded 31,015 records; after removal of duplicates, 14,765 records were sifted by title and  
99 abstract (Figure 1). Forty-four articles were included: 25 primary research reports (Table 2) and 19  
100 systematic reviews (Supplementary table 3). Six TB IPC guidelines were also reviewed for possible primary  
101 research articles (Supplementary 3). Of the 25 studies, 17 (68%) were conducted in North America, three  
102 (12%) in sub-Saharan Africa, two (8%) in each of Europe and Latin America, and one (4%) in East Asia; 19  
103 (76%) were conducted in low TB burden (all high-income countries) and six (24%) in high TB burden settings  
104 (five upper middle- and one low-income country); and 24 (96%) were conducted in hospitals and one (4%) in  
105 primary care facilities. Only two (8%) studies reported outcomes in non-HCWs attending health care  
106 facilities; in both cases these were HIV-positive in-patients. Nineteen (76%) studies described LTBI incidence  
107 and seven (28%) described TB disease incidence (one described LTBI and TB disease incidence).

108 Sixteen (64%) of 25 studies implemented interventions of interest in combination: 11 triage and isolation;  
109 two isolation and effective treatment; and three triage, isolation, and effective treatment (Figure 2, panel A).  
110 Of the remainder, eight (32%) studies assessed isolation alone and one (4%) assessed triage alone. An  
111 obstacle to the evaluation of the three IPC interventions of interest was the paucity of studies that  
112 introduced only these interventions: all studies, except two,<sup>21,22</sup> implemented any or all of the three  
113 interventions as part of a wider suite of measures, including personal protective equipment (PPE) for HCWs;  
114 changes to ventilation and other environmental controls; and broader administrative controls (Table 3;  
115 Figure 2, panel B). Disaggregation of the effects of individual measures was not possible and it was therefore  
116 not feasible to attribute the entire reported effect on outcomes to a single intervention, or to estimate the

117 proportion of a demonstrated effect that could be attributed to the intervention (whether one, two, or all  
118 three elements of interest).

### 119 **Studies implementing triage of people with TB signs and/or symptoms**

120 Fifteen studies implemented triage: 11 (73%) in low burden settings, all in secondary or tertiary health  
121 facilities. Definitions of triage varied widely, from screening of patients “with pneumonia or evidence of  
122 TB”,<sup>35</sup> to an “expanded respiratory isolation policy”.<sup>37,41</sup> The only study to use triage alone used “routine  
123 chest x-ray screening for all new admissions”.<sup>21</sup>

124 Among 10 studies reporting changes in LTBI incidence (all implemented composite interventions), estimates  
125 of effect ranged from an absolute reduction of 2.3% (n = 21,197)<sup>41</sup> to 20.5% (n = 65; Table 4).<sup>48</sup> Of the four  
126 studies reporting incidence rates (IRs),<sup>28,32,37,38</sup> IR ratios ranged from 0.18 to 0.9 (unadjusted; some  
127 calculated).

128 Six studies reported changes in TB disease incidence; one that used only triage reported 78 episodes in  
129 38,331 PY before versus 12 episodes in 18,229 PY after implementation (calculated IR ratio 0.32).<sup>21</sup> Two  
130 other studies in low burden settings also showed reduced risk/incidence after implementation of composite  
131 interventions.<sup>34,47</sup> In contrast, three studies in high burden settings<sup>24,28,29</sup> showed small or no reductions in  
132 risk/incidence after use of triage (and other interventions), from 3.7% to 3.2%,<sup>29</sup> 0.65 to 0.44 per 100 PY,<sup>28</sup>  
133 and an adjusted odds ratio (OR) of 0.97 (95% CI 0.90–1.04)<sup>24</sup> comparing hospitals with higher versus lower  
134 administrative scores (Table 4).

### 135 **Studies implementing isolation or spatial separation**

136 Twenty-four studies<sup>22,24–29,31–38,40–43,45–49</sup> implemented respiratory isolation or spatial separation; 18/24 (75%)  
137 were in low burden countries. All studies, except one,<sup>22</sup> used isolation together with other TB IPC measures.

138 Among the 19 studies<sup>22,26–28,31–33,35–38,40–43,45,46,48,49</sup> reporting differences in LTBI incidence, effects ranged from  
139 a 1% increase (n = 4,060)<sup>33</sup> to a 20.5% reduction (n = 65; Table 4).<sup>48</sup> The two largest studies (one each in the

140 USA and Brazil) showed absolute reductions in LTBI incidence (1.2%<sup>42</sup> and 1.7%).<sup>27</sup> Among six studies  
141 reporting IRs, IR ratios (intervention versus no intervention) ranged from 0.01 (95% CI 0–0.04;  $p < 0.001$ ;  
142 adjusted, covariates unclear)<sup>28</sup> to 0.24 (95% CI 0.10–0.54; adjusted for exposure and occupation)<sup>26</sup> and 0.46  
143 (calculated from data).<sup>38</sup> Among the six studies that reported changes in TB disease, estimates of effect  
144 differed by setting, from almost no difference in incidence in the four studies in high burden settings,<sup>24,25,28,29</sup>  
145 to absolute reductions of 6% ( $n = 409$ )<sup>47</sup> and 29% ( $n = 134$ ; calculated)<sup>34</sup> in low burden settings.

### 146 **Studies implementing effective treatment based on drug susceptibility**

147 Five studies<sup>31,45–48</sup> used effective treatment with other IPC measures. ‘Effective treatment’ was defined  
148 variably, from a change in regimen from three to four drugs,<sup>48</sup> to the use of “radiometric susceptibility  
149 testing,”<sup>31</sup> which, it was assumed, would have led to appropriate treatment, though this is not stated.

150 Two studies did not report outcomes for all participants/sites.<sup>31,45</sup> All studies showed absolute reductions in  
151 TST conversion after implementation of IPC measures, ranging from 2.1%<sup>46</sup> to 20.5%<sup>48</sup> (crude; calculated),  
152 though all studies had small numbers of outcomes (range 10–104) and two had small sample sizes ( $n \leq 650$ ).

153 Only one study<sup>47</sup> used effective treatment and measured TB disease incidence, employing an “expanded  
154 anti-TB regimen” (a change from median 1.5 [range 0–4] to 2.0 [range 0–4] drugs) as part of a composite  
155 intervention that included triage, isolation, and changes to diagnostic processes. They found a change in TB  
156 disease risk (or “attack rate”) among HIV-positive individuals admitted to the ward, from 8.8% before, to  
157 2.6% after intervention ( $p = 0.01$ ).

### 158 **Quality assessment and GRADE**

159 All 18 retrospective studies scored poorly (median 10/27 [IQR 8.3–12.0; range 6–13]; Table 5). The seven  
160 prospective studies also scored poorly (Table 6): one study was marked down for incomplete outcome  
161 reporting and three for selective outcome reporting. The overall low study quality was reflected in the  
162 GRADE assessment (Appendix 3; Supplementary tables 4–9), where the strength of evidence was

163 consistently downgraded due to serious risk of bias and very serious indirectness (the latter often due to the  
164 concurrent use of multiple IPC measures).

## 165 **Discussion**

---

166 This review found 25 studies, published from 1957–2017, that reported the effects of triage, isolation, and  
167 effective treatment on the incidence of LTBI or TB disease in HCWs and others attending health facilities.  
168 Most studies were conducted in the 1990s in USA hospitals, several in response to outbreaks of TB.<sup>22,34,45–48</sup>  
169 Almost all studies showed reduced LTBI or TB disease incidence after implementation of a package of IPC  
170 measures, but, because of heterogeneity in study design and reporting of results, meta-analysis was not  
171 conducted. Studies were generally of low quality. All studies, except two, tested composite interventions,  
172 including other administrative measures, PPE, and environmental measures; it was therefore not possible to  
173 disaggregate the effects of specific interventions from those of the others described.

174 It is important that these findings should not be interpreted to suggest a lack of efficacy of the TB IPC  
175 measures examined; effective treatment, in particular, is supported by studies outside health care settings<sup>50</sup>  
176 and studies from health care settings using guinea pigs as infection endpoints.<sup>13</sup> Indeed the WHO 2019 TB  
177 IPC guidelines recommend all three examined measures as first-line controls to be used as part of broad  
178 suite of interventions.<sup>12</sup> Statements, in the guidelines, around “low certainty” and “indirectness” reflect the  
179 overall poor study quality, heterogeneity in study design, implementation of multiple interventions at one  
180 time, predominance of studies from a particular type of setting, and deficiencies in the reporting of results.  
181 These issues are discussed below.

### 182 **Gaps in the literature**

183 Most studies were from high-income, low TB burden settings, predominantly the USA. Conspicuously absent  
184 were countries with very high TB burdens, such as India and China, and countries in sub-Saharan Africa and  
185 South or Central America (other than South Africa, Malawi, and Brazil), where the LTBI burden among HCWs



186 is known to be very high.<sup>3,4</sup> Data from these countries are essential if global policy is to address successfully  
187 the broad range of environments in which IPC measures must be implemented.

188 Only one study was conducted in a primary care setting.<sup>25</sup> Though many people with TB in low burden  
189 countries may receive treatment in hospitals, most in high burden countries are cared for as out-patients  
190 and may not visit a hospital at any point in their illness.<sup>51</sup> WHO widely recommends the decentralisation of  
191 TB care,<sup>52,53</sup> though for DR-TB this policy is variably effected.<sup>2</sup> As shown in South Africa,<sup>54–57</sup> HCWs in clinics  
192 and the community are also at high risk of TB infection and disease. Evidence is still needed for the  
193 effectiveness of IPC measures in these environments, which present different challenges for implementing  
194 interventions and measuring outcomes.<sup>58,59</sup>

195 Many studies provided detailed descriptions of interventions used but often did not describe, in any depth,  
196 fidelity to these interventions. Cross-sectional studies<sup>24,25,40,42</sup> were the weakest in this regard, as they were  
197 able only to assess whether an intervention or policy had been instated, and not if it was being applied as  
198 intended. (Additional methodological shortcomings in some cross-sectional studies further reduced  
199 confidence in their findings; for example, the study by Claassens et al.,<sup>25</sup> where IPC coverage was estimated  
200 after the period during which outcomes were enumerated.) Some reporting of fidelity is essential to  
201 strengthen what is already very indirect evidence for the effectiveness of these interventions.

202 A consistent finding was the lack of reporting of secular changes in TB incidence or prevalence among people  
203 attending the facility over the course of the study. This is particularly relevant given the high number of  
204 before-after or during-after studies included, where the same facility/ies at different time points served as  
205 control and intervention. Changes in the numbers of potentially infectious individuals attending study  
206 facility/ies may have had a dramatic effect on the risk of MTB transmission to HCWs, and reductions in LTBI  
207 or active TB incidence may have been misattributed to the implementation of IPC measures. Measurement  
208 of secular changes is recommended by guidance on conducting before-after studies<sup>19</sup> and should be a  
209 standard reporting requirement for future studies.

210 Incidence of LTBI or TB disease in HCWs are useful ways to estimate MTB transmission from patients in  
211 health care settings. Transmission between patients and from HCWs to patients does, of course, occur,  
212 though this was measured by only two studies, both in low TB burden, high-income countries.<sup>34,47</sup> Choice of  
213 at-risk population, outcomes, and outcome measurement are critical when studying MTB transmission, but  
214 can also make study design more complex.<sup>60</sup> In high TB burden countries, a high proportion of HCWs already  
215 have LTBI, limiting the size of the at-risk population. Using TST to measure LTBI incidence (as in several of the  
216 included studies) can also be problematic, as reactions can vary based on host factors. The development of  
217 TB disease, though easier to measure, is also dependent on a number of interconnected host factors and, in  
218 the absence of complementary molecular epidemiological data, is more difficult to reliably attribute to a  
219 congregate setting transmission event. More detailed descriptions of at-risk HCW populations would allow  
220 for better extrapolation of findings to other key populations, particularly HIV-positive individuals, and  
221 provide better guidance on how to prevent TB in HCWs. As discussed by Harries et al.,<sup>29</sup> robust occupational  
222 health programmes are critical to the well-being of frontline HCWs; embedding TB IPC studies within existing  
223 occupational health frameworks may allow for better reporting of individual HCW risk profiles and improve  
224 long-term fidelity to interventions.

## 225 **Future research**

226 This review, like others,<sup>4,6,7,11,61</sup> found limited and low quality evidence for the effectiveness of administrative  
227 IPC measures in reducing MTB transmission, with over-representation of data from hospitals in high-income,  
228 low TB burden countries. Like previous reviewers, we call for better designed and implemented studies from  
229 a wider variety of settings, though we acknowledge the difficulties of doing this in what are often  
230 unpredictable environments and recognise the shortcomings in the methods available to measure MTB  
231 transmission in these settings.<sup>62,63</sup>

232 Despite the weaknesses in the data presented here, the weight of evidence to support the use of established  
233 TB IPC measures is sufficient that it would be unethical to conduct randomised trials involving a true 'control'  
234 arm, though trials comparing 'best practice' IPC interventions with an established basic standard of care

235 should still be considered, as should the use of pragmatic trial designs, such as stepped wedge cluster  
236 randomised trials.<sup>64</sup> We would suggest a change in expectations and an acceptance of the limitations  
237 inherent in conducting these complex interventional studies in challenging clinical settings. Standardisation  
238 of study designs, outcome measurement, and reporting formats, with replication of clusters or sites would  
239 facilitate the generation of more robust data syntheses to guide policymaking, as would efforts by  
240 investigators to provide more precise and comprehensive data in the areas discussed above. We suggest  
241 that greater numbers of imperfect but comparable data from studies conducted in a wide range of settings  
242 that adhere to a set of standardised rules around design and reporting would be more useful to decision-  
243 making than a few perfectly-designed studies conducted in places unrepresentative of those where effective  
244 interventions are most needed. Additionally, quasi-experimental techniques, such as interrupted time-series  
245 analysis,<sup>65–67</sup> with or without controls,<sup>68</sup> or difference of differences approaches have been employed with  
246 success in evaluating complex public health policy interventions in rapidly changing environments<sup>69</sup> and  
247 should be considered seriously for future real-world estimations of the effectiveness of TB IPC measures. To  
248 this end, given the difficulties outlined above around measurement of outcomes, confounding, bundling of  
249 interventions, and valid comparator groups, it would be beneficial to have additional specific guidance,  
250 developed by relevant experts, to help investigators plan, conduct, and report studies examining the efficacy  
251 of measures to reduce MTB transmission.

## 252 **Limitations and strengths**

253 ‘Prompt initiation of effective treatment’ is widely considered a reliable way to reduce MTB transmission  
254 and is the wording used in the WHO 2019 TB IPC guidelines.<sup>12</sup> The five studies included in this review that  
255 used effective treatment did not report time to treatment and, because ‘prompt initiation of effective  
256 treatment’ was not one of the defined interventions of interest, studies examining its efficacy in reducing  
257 transmission were not included for analysis.

258 Heterogeneity of the data and weaknesses in study design prevented meaningful quantitative synthesis,  
259 which may have provided a clearer guide for policymakers. Studies may have been overlooked during sifting

260 or published in non-specified languages. Strengths include the application of a robust search strategy by a  
261 professional librarian across a wide range of repositories, all sifting and data extraction being done in  
262 duplicate (per PRISMA recommendations; Appendix 4),<sup>70</sup> and the use of GRADE to assess quality.

## 263 **Conclusions**

---

264 This review found 25 studies implementing triage, isolation, or effective treatment and measuring the  
265 incidence of LTBI or TB disease or both. Overall, packages of IPC measures appeared to reduce MTB  
266 transmission, but studies were of low quality and evidence for the effectiveness of individual or combined  
267 measures was indirect and of limited utility; heterogeneity of the data prevented meta-analysis. More data  
268 are needed from high-burden, lower-income, primary care settings. Harmonisation of study designs and  
269 reporting frameworks will allow for more formal data syntheses, creating a better platform for policymaking.  
270 The development of specific guidance around conducting and reporting studies to determine the efficacy of  
271 TB IPC measures should be prioritised by governing and stakeholder bodies.

## 272 **Funding**

---

273 This work was supported by the World Health Organization (reference 2017/748478-0) and the Medical  
274 Research Council, UK (reference MR/K012126/1). The funders had no role in study design, data collection  
275 and analysis, decision to publish, or preparation of the manuscript.

## 276 **Acknowledgments**

---

277 Thanks to Lice González-Angulo, Fuad Mirzayev, Thomas Piggott, and Holger Schünemann for their guidance  
278 and help with GRADE, in particular.

## 279 **Author contributions**

---

280 Conceptualisation: ASK, DAJM, JF, KLF, RCH

281 Data curation: ASK, KLF, RCH

282 Formal analysis: ASK, KLF, MG  
283 Funding acquisition: DAJM, KLF  
284 Investigation: ASK, DAJM, HEB, IG, JE, JF, KLF, MC, MG, MT, RCH  
285 Methodology: ASK, DAJM, JF, KLF, MG, RCH  
286 Project administration: ASK, DAJM, KLF, RCH  
287 Resources: JF, MG, RCH  
288 Software: n/a  
289 Supervision: DAJM, KLF, RCH  
290 Visualisation: ASK  
291 Writing – original draft: ASK, KLF  
292 Writing – review & editing: ASK, DAJM, HEB, IG, JE, JF, KLF, MC, MG, MT, RCH

## 293 **Competing interests**

---

294 The authors declare no competing interests.

## 295 **References**

---

- 296 1 Abajobir AA, Abbafati C, Abbas KM, et al. Global, regional, and national age-sex specific mortality for 264 causes  
297 of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. *The Lancet*.  
298 2017;**390**(10100):1151–210.
- 299 2 World Health Organization. Global tuberculosis report. 2018.  
300 <http://apps.who.int/iris/bitstream/handle/10665/274453/9789241565646-eng.pdf?ua=1> (accessed 2018 Sep  
301 30)
- 302 3 Joshi R, Reingold AL, Menzies D, Pai M. Tuberculosis among health-care workers in low- and middle-income  
303 countries: A systematic review. *PLoS Med*. 2006;**3**(12):2376–91.
- 304 4 Menzies D, Joshi R, Pai M. Risk of tuberculosis infection and disease associated with work in health care  
305 settings. *Int J Tuberc Lung Dis*. 2007;**11**(6):593–605.
- 306 5 Uden L, Barber E, Ford N, Cooke GS. Risk of Tuberculosis Infection and Disease for Health Care Workers: An  
307 Updated Meta-Analysis. *Open Forum Infect Dis*. 2017;**4**(3):ofx137.
- 308 6 Menzies D, Fanning A, Yuan L, Fitzgerald M. Tuberculosis among health care workers. *N Engl J Med*.  
309 1995;**332**(2):92–8.
- 310 7 Joshi R, Reingold AL, Menzies D, Pai M. Tuberculosis among health-care workers in low- and middle-income  
311 countries: a systematic review. *PLoS Med Public Libr Sci*. 2006;**3**(12):e494–e494.
- 312 8 Centers for Disease Control and Prevention (CDC). Tuberculosis infection control.  
313 <https://www.cdc.gov/tb/topic/infectioncontrol/default.htm> (accessed 2018 Aug 2)

- 314 9 World Health Organization. WHO Policy on TB Infection Control in Health-Care Facilities, Congregate Settings  
315 and Households. 2009. [http://www.who.int/tb/publications/2009/infection\\_control/en/](http://www.who.int/tb/publications/2009/infection_control/en/) (accessed 2018 Mar  
316 22)
- 317 10 Jensen PA, Lambert LA, Iademarco MF, Ridzon R, CDC. Guidelines for preventing the transmission of  
318 Mycobacterium tuberculosis in health-care settings, 2005. *MMWR Recomm Rep Morb Mortal Wkly Rep*  
319 *Recomm Rep.* 2005;**54**(RR-17):1–141.
- 320 11 Schmidt B-M, Engel ME, Abdullahi L, Ehrlich R. Effectiveness of control measures to prevent occupational  
321 tuberculosis infection in health care workers: a systematic review. *BMC Public Health.* 2018;**18**(1):661.
- 322 12 World Health Organization. WHO guidelines on tuberculosis infection prevention and control, 2019 update.  
323 2019. <https://apps.who.int/iris/bitstream/handle/10665/311259/9789241550512-eng.pdf?ua=1> (accessed  
324 2019 Oct 16)
- 325 13 World Health Organization. WHO guidelines on tuberculosis infection prevention and control, 2019 update.  
326 Online annex 6: Results of the systematic reviews. 2019. [https://www.who.int/tb/areas-of-work/preventive-  
327 care/infection-control/Annex6-SystematicReviewsResults.pdf?ua=1&ua=1](https://www.who.int/tb/areas-of-work/preventive-care/infection-control/Annex6-SystematicReviewsResults.pdf?ua=1&ua=1) (accessed 2019 Oct 16)
- 328 14 Fielding KL, Harris RC, Karat AS, Falconer J, Moore DAJ. Systematic review for evidence of administrative  
329 infection control interventions to reduce tuberculosis transmission and three related background questions:  
330 Study protocol. PROSPERO 2018 CRD42018085226. 2018.  
331 [http://www.crd.york.ac.uk/PROSPERO/display\\_record.php?ID=CRD42018085226](http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018085226) (accessed 2018 Apr 30)
- 332 15 World Health Organization. Use of high burden country lists for TB by WHO in the post-2015 era. 2016.  
333 [http://www.who.int/tb/publications/global\\_report/high\\_tb\\_burden-countrylists2016-2020.pdf?ua=1](http://www.who.int/tb/publications/global_report/high_tb_burden-countrylists2016-2020.pdf?ua=1) (accessed  
334 2018 Mar 2)
- 335 16 Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both  
336 of randomised and non-randomised studies of health care interventions. *J Epidemiol Community Health.*  
337 1998;**52**(6):377–84.
- 338 17 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Intervention Version 5.1 (updated  
339 March 2011). The Cochrane Collaboration. 2011. <http://handbook.cochrane.org> (accessed 2018 Apr 30)
- 340 18 West S, King V, Carey TS, et al. Systems to rate the strength of scientific evidence. *Evid Rep Technol Assess*  
341 *(Summ).* 2002;**(47)**:1–11.
- 342 19 Goodacre S. Uncontrolled before-after studies: discouraged by Cochrane and the EMJ. *Emerg Med J.*  
343 2015;**32**(7):507–8.
- 344 20 World Bank. World Bank Country and Lending Groups: Historic Classification (1987–2015). 2016.  
345 <http://databank.worldbank.org/data/download/site-content/OGHIST.xls> (accessed 2016 Dec 31)
- 346 21 Jacobson G, Hoyt DD, Bogen E. Tuberculosis in hospital employees as affected by an admission chest X-ray  
347 screening program. *Dis Chest.* 1957;**32**(1):27–38.
- 348 22 Uyamadu N, Ahkee S, Carrico R, Tolentino A, Wojda B, Ramirez J. Reduction in tuberculin skin-test conversion  
349 rate after improved adherence to tuberculosis isolation. *Infect Control Hosp Epidemiol.* 1997;**18**(8):575–9.
- 350 23 Oliveros J. Venny. An interactive tool for comparing lists with Venn’s diagrams. 2015.  
351 <http://bioinfo.gp.cnb.csic.es/tools/venny/index.html> (accessed 2018 Apr 30)
- 352 24 O’Hara LM, Yassi A, Bryce EA, et al. Infection control and tuberculosis in health care workers: an assessment of  
353 28 hospitals in South Africa. *Int J Tuberc Lung Dis.* 2017;**21**(3):320–6.
- 354 25 Claassens MM, van Schalkwyk C, du Toit E, et al. Tuberculosis in healthcare workers and infection control  
355 measures at primary healthcare facilities in South Africa. *PLoS ONE Electron Resour.* 2013;**8**(10):e76272–  
356 e76272.
- 357 26 da Costa PA, Trajman A, Mello FC, et al. Administrative measures for preventing Mycobacterium tuberculosis  
358 infection among healthcare workers in a teaching hospital in Rio de Janeiro, Brazil. *J Hosp Infect.* 2009;**72**(1):57–  
359 64.
- 360 27 Roth VR, Garrett DO, Laserson KF, et al. A multicenter evaluation of tuberculin skin test positivity and  
361 conversion among health care workers in Brazilian hospitals. *Int J Tuberc Lung Dis.* 2005;**9**(12):1335–42.

- 362 28 Yanai H, Limpakarnjanarat K, Uthaiworavit W, Mastro TD, Mori T, Tappero JW. Risk of Mycobacterium  
363 tuberculosis infection and disease among health care workers, Chiang Rai, Thailand. *Int J Tuberc Lung Dis.*  
364 2003;**7**(1):36–45.
- 365 29 Harries AD, Hargreaves NJ, Gausi F, Kwanjana JH, Salaniponi FM. Preventing tuberculosis among health workers  
366 in Malawi. *Bull World Health Organ.* 2002;**80**(7):526–31.
- 367 30 Harries AD, Nyirenda TE, Banerjee A, Boeree MJ, Salaniponi FM. Tuberculosis in health care workers in Malawi.  
368 *Trans R Soc Trop Med Hyg.* 1999;**93**(1):32–5.
- 369 31 Welbel SF, French AL, Bush P, DeGuzman D, Weinstein RA. Protecting health care workers from tuberculosis: a  
370 10-year experience. *Am J Infect Control.* 2009;**37**(8):668–73.
- 371 32 Baussano I, Bugiani M, Carosso A, et al. Risk of tuberculin conversion among healthcare workers and the  
372 adoption of preventive measures. *Occup Environ Med.* 2007;**64**(3):161–6.
- 373 33 Jones SG. Evaluation of a human immunodeficiency virus rule out tuberculosis critical pathway as an  
374 intervention to decrease nosocomial transmission of tuberculosis in the inpatient setting. *AIDS Patient Care*  
375 *Stds.* 2002;**16**(8):389–94.
- 376 34 Moro ML, Errante I, Infuso A, et al. Effectiveness of infection control measures in controlling a nosocomial  
377 outbreak of multidrug-resistant tuberculosis among HIV patients in Italy. *Int J Tuberc Lung Dis.* 2000;**4**(1):61–8.
- 378 35 Bangsberg DR, Crowley K, Moss A, Dobkin JF, McGregor C, Neu HC. Reduction in tuberculin skin-test  
379 conversions among medical house staff associated with improved tuberculosis infection control practices. *Infect*  
380 *Control Hosp Epidemiol.* 1997;**18**(8):566–70.
- 381 36 Behrman AJ, Shofer FS. Tuberculosis exposure and control in an urban emergency department. *Ann Emerg Med.*  
382 1998;**31**(3):370–5.
- 383 37 Blumberg HM, Sotir M, Erwin M, Bachman R, Shulman JA. Risk of house staff tuberculin skin test conversion in  
384 an area with a high incidence of tuberculosis. *Clin Infect Dis.* 1998;**27**(4):826–33.
- 385 38 Louthier J, Rivera P, Feldman J, Villa N, DeHovitz J, Sepkowitz KA. Risk of tuberculin conversion according to  
386 occupation among health care workers at a New York City hospital. *Am J Respir Crit Care Med.*  
387 1997;**156**(1):201–5.
- 388 39 Fella P, Rivera P, Hale M, Squires K, Sepkowitz K. Dramatic decrease in tuberculin skin test conversion rate  
389 among employees at a hospital in New York City. *Am J Infect Control.* 1995;**23**(6):352–6.
- 390 40 Sinkowitz RL, Fridkin SK, Manangan L, Wenger PN, Jarvis WR. Status of tuberculosis infection control programs  
391 at United States hospitals, 1989 to 1992. *Am J Infect Control.* 1996;**24**(4):226–34.
- 392 41 Blumberg HM, Watkins DL, Berschling JD, et al. Preventing the nosocomial transmission of tuberculosis. *Ann*  
393 *Intern Med.* 1995;**122**(9):658–63.
- 394 42 Fridkin SK, Manangan L, Bolyard E, Jarvis WR. SHEA-CDC TB survey, Part II: Efficacy of TB infection control  
395 programs at member hospitals, 1992. Society for Healthcare Epidemiology of America. *Infect Control Hosp*  
396 *Epidemiol.* 1995;**16**(3):135–40.
- 397 43 Holzman RS. A comprehensive control program reduces transmission of tuberculosis to hospital staff (Abstract  
398 80, 33rd Annual Meeting of the Infectious Diseases Society of America, San Francisco, USA). *Clin Infect Dis.*  
399 1995;**21**(733).
- 400 44 Centers for Disease Control and Prevention. Guidelines for preventing the transmission of Mycobacterium  
401 tuberculosis in health-care facilities, 1994. *Morb Mortal Wkly Rep Recomm Rep.* 1994;**43**(RR-13):1–132.
- 402 45 Jarvis WR. Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis. *Am J Infect Control.*  
403 1995;**23**(2):146–51.
- 404 46 Maloney SA, Pearson ML, Gordon MT, Del Castillo R, Boyle JF, Jarvis WR. Efficacy of control measures in  
405 preventing nosocomial transmission of multidrug-resistant tuberculosis to patients and health care workers.  
406 *Ann Intern Med.* 1995;**122**(2):90–5.
- 407 47 Stroud LA, Tokars JI, Grieco MH, et al. Evaluation of infection control measures in preventing the nosocomial  
408 transmission of multidrug-resistant Mycobacterium tuberculosis in a New York City hospital. *Infect Control Hosp*

- 409 *Epidemiol Off J Soc Hosp Epidemiol Am.* 1995;**16**(3):141–7.
- 410 48 Wenger PN, Otten J, Breeden A, Orfas D, Beck-Sague CM, Jarvis WR. Control of nosocomial transmission of  
411 multidrug-resistant Mycobacterium tuberculosis among healthcare workers and HIV-infected patients. *Lancet.*  
412 1995;**345**(8944):235–40.
- 413 49 Bryan CS. The hospital tuberculosis registry: an aid to infection control. *Am J Infect Control.* 1983;**11**(2):57–62.
- 414 50 World Health Organization. Guiding principles to reduce tuberculosis transmission in the WHO European  
415 Region. 2018. [http://www.euro.who.int/\\_\\_data/assets/pdf\\_file/0008/377954/ic-principles-eng.pdf?ua=1](http://www.euro.who.int/__data/assets/pdf_file/0008/377954/ic-principles-eng.pdf?ua=1)  
416 (accessed 2019 Oct 14)
- 417 51 Atun R, Weil DE, Eang MT, Mwakiyusa D. Health-system strengthening and tuberculosis control. *The Lancet.*  
418 2010;**375**(9732):2169–78.
- 419 52 World Health Organization Regional Office for Europe. A people-centred model of tuberculosis care. 2017.  
420 [http://www.euro.who.int/\\_\\_data/assets/pdf\\_file/0004/342373/TB\\_Content\\_WHO\\_PRO\\_eng\\_final.pdf?ua=1](http://www.euro.who.int/__data/assets/pdf_file/0004/342373/TB_Content_WHO_PRO_eng_final.pdf?ua=1)  
421 (accessed 2018 Nov 12)
- 422 53 World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. 2011.  
423 [http://apps.who.int/iris/bitstream/handle/10665/44597/9789241501583\\_eng.pdf;jsessionid=FA87F46792A86A](http://apps.who.int/iris/bitstream/handle/10665/44597/9789241501583_eng.pdf;jsessionid=FA87F46792A86A06AED0D6E1CFE6A1DB?sequence=1)  
424 [06AED0D6E1CFE6A1DB?sequence=1](http://apps.who.int/iris/bitstream/handle/10665/44597/9789241501583_eng.pdf;jsessionid=FA87F46792A86A06AED0D6E1CFE6A1DB?sequence=1) (accessed 2018 Nov 13)
- 425 54 Mahomed S, Khilawan D, Knight S. Tuberculosis among public sector healthcare workers in eThekweni District,  
426 KwaZulu-Natal. *Occup Health South Afr.* 2016;**22**(5).
- 427 55 O’Hara LM, Yassi A, Zungu M, et al. The neglected burden of tuberculosis disease among health workers: a  
428 decade-long cohort study in South Africa. *BMC Infect Dis.* 2017;**17**(1):547.
- 429 56 Claassens MM, Sismanidis C, Lawrence KA, et al. Tuberculosis among community-based health care researchers.  
430 *Int J Tuberc Lung Dis.* 2010;**14**(12):1576–81.
- 431 57 Grobler L, Mehtar S, Dheda K, et al. The epidemiology of tuberculosis in health care workers in South Africa: a  
432 systematic review. *BMC Health Serv Res.* 2016;**16**(1):416.
- 433 58 Druetz T. Integrated primary health care in low- and middle-income countries: a double challenge. *BMC Med*  
434 *Ethics.* 2018;**19**(Suppl 1):48.
- 435 59 Lewin S, Lavis JN, Oxman AD, et al. Supporting the delivery of cost-effective interventions in primary health-care  
436 systems in low-income and middle-income countries: an overview of systematic reviews. *Lancet Lond Engl.*  
437 2008;**372**(9642):928–39.
- 438 60 Yates TA, Khan PY, Knight GM, et al. The transmission of Mycobacterium tuberculosis in high burden settings.  
439 *Lancet Infect Dis.* 2016;**16**(2):227–38.
- 440 61 Harries AD, Maher D, Nunn P. Practical and affordable measures for the protection of health care workers from  
441 tuberculosis in low-income countries. *Bull World Health Organ.* 1997;**75**(5):477–89.
- 442 62 Dowdy DW, Grant AD, Dheda K, Nardell E, Fielding K, Moore DAJ. Designing and Evaluating Interventions to Halt  
443 the Transmission of Tuberculosis. *J Infect Dis.* 2017;**216**:s654–61.
- 444 63 Mathema B, Andrews JR, Cohen T, et al. Drivers of Tuberculosis Transmission. *J Infect Dis.* 2017;**216**:S644–53.
- 445 64 Hemming K, Haines TP, Chilton PJ, Girling AJ, Lilford RJ. The stepped wedge cluster randomised trial: rationale,  
446 design, analysis, and reporting. *BMJ.* 2015;**350**:h391.
- 447 65 Bernal JL, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of public health  
448 interventions: a tutorial. *Int J Epidemiol.* 2017;**46**(1):348–55.
- 449 66 Kontopantelis E, Doran T, Springate DA, Buchan I, Reeves D. Regression based quasi-experimental approach  
450 when randomisation is not an option: interrupted time series analysis. *BMJ.* 2015;**350**:h2750.
- 451 67 Penfold RB, Zhang F. Use of Interrupted Time Series Analysis in Evaluating Health Care Quality Improvements.  
452 *Acad Pediatr.* 2013;**13**(6):S38–44.
- 453 68 Lopez Bernal J, Cummins S, Gasparrini A. The use of controls in interrupted time series studies of public health  
454 interventions. *Int J Epidemiol.* 2018;



455 69 Biglan A, Ary D, Wagenaar AC. The value of interrupted time-series experiments for community intervention  
456 research. *Prev Sci Off J Soc Prev Res.* 2000;1(1):31–49.

457 70 Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-  
458 analyses of studies that evaluate health care interventions: Explanation and elaboration. *PLoS Med.* 2009;6(7).  
459  
460

461 **Tables and figures**

462 **Table 1. Inclusion and exclusion criteria used during sifting process**

| Inclusion criteria               |   | Exclusion criteria  |
|----------------------------------|---|---|
| <b>Types of participants</b>     | Studies of:<br>1) HCWs (including CHWs) working in health care settings; or<br>2) Other staff working in a health care setting; or<br>3) Persons of all ages (patients and visitors) attending health care settings, anywhere in the world.   | <ol style="list-style-type: none"> <li>1. Any study not in humans</li> <li>2. Any study that did not report any of the above-stated outcomes of interest</li> <li>3. Any study reporting solely on primary outcomes of interest without a control or comparator group.</li> <li>4. Any systematic review superseded by an updated systematic review</li> <li>5. Narrative reviews not adding new data or new analysis of data to existing knowledge</li> <li>6. Commentaries and mathematical modelling studies</li> <li>7. Studies with fewer than 10 participants per comparator arm</li> <li>8. Any study not written in English, Japanese, Chinese, Russian, French, Spanish or Portuguese</li> <li>9. Any study published before 1946</li> </ol> |
| <b>Types of intervention</b>     | At least one of:<br>1) Triage of people with TB signs or TB symptoms or confirmed TB;<br>2) Respiratory isolation (spatial separation) of presumed infectious TB cases; or<br>3) Effective treatment of TB based on bacteriologic susceptibility  |   |
| <b>Types of comparator</b>       | Studies reporting data (for outcomes of interest) from a control or comparator group of HCWs (including CHWs) working in health care settings, or other staff or persons of all ages (patients and visitors) attending health care settings, with no or different administrative infection control interventions. |   |
| <b>Types of outcome measures</b> | Studies reporting data on at least one of the outcome measures of interest (incidence/prevalence of LTBI or TB disease).  |   |
| <b>Types of study</b>            | Any consecutive case series, case control study, cohort study, randomised controlled study, systematic review, or meta-analysis.  |   |

463 CHW: community health workers; HCWs: health care workers; LTBI: latent tuberculosis infection; TB: tuberculosis

464

**Table 2. Summary of characteristics of primary research studies included (n = 25)**

| Characteristic                    | Number of studies conducted |                                     |                                     |
|-----------------------------------|-----------------------------|-------------------------------------|-------------------------------------|
|                                   | Overall, n (%/25)           | In low burden* countries, n (row %) | In high burden* countries, n (row%) |
| <b>All</b>                        | <b>25 (100)</b>             | <b>19 (76.0)†</b>                   | <b>6 (24.0)‡</b>                    |
| <b>Period conducted§</b>          |                             |                                     |                                     |
| Pre-1990                          | 2 (8.0)                     | 2 (100)                             | 0                                   |
| 1990–1999                         | 17 (68.0)                   | 15 (88.2)                           | 2 (11.8)                            |
| 2000–2009                         | 5 (20.0)                    | 2 (40.0)                            | 3 (60.0)                            |
| 2010 and later                    | 1 (4.0)                     | 0                                   | 1 (100)                             |
| <b>Study design</b>               |                             |                                     |                                     |
| Cross-sectional                   | 5 (20.0)                    | 2 (40.0)                            | 3 (60.0)                            |
| Before/after                      | 12 (48.0)                   | 10 (83.3)                           | 2 (16.7)                            |
| During/after                      | 8 (32.0)                    | 7 (87.5)                            | 1 (12.5)                            |
| <b>Level of facility</b>          |                             |                                     |                                     |
| Primary                           | 1 (4.0)                     | 0                                   | 1 (100)                             |
| Secondary/tertiary                | 24 (96.0)                   | 19 (79.2)                           | 5 (20.8)                            |
| <b>Group/s studied</b>            |                             |                                     |                                     |
| HCWs                              | 23 (92.0)                   | 17 (73.9)                           | 6 (26.1)                            |
| Other individuals                 | 2 (8.0)                     | 2 (100)                             | 0                                   |
| <b>Interventions implemented¶</b> |                             |                                     |                                     |
| Triage                            | 15 (60.0)                   | 11 (73.3)                           | 4 (26.7)                            |
| Isolation                         | 24 (96.0)                   | 18 (75.0)                           | 6 (25.0)                            |
| Effective treatment               | 5 (20.0)                    | 5 (100)                             | 0                                   |
| <b>Outcomes measured  </b>        |                             |                                     |                                     |
| LTBI incidence**                  | 19 (76.0)                   | 16 (84.2)                           | 3 (15.8)                            |
| TB disease incidence**            | 7 (28.0)                    | 3 (42.9)                            | 4 (57.1)                            |

466

\*Based on WHO 2016 definitions<sup>15</sup>

467

†Of the 19 studies in low burden countries, 17 (89%) were conducted in North America and two (11%) in Europe; all 19 were conducted in high-income countries (per World Bank classifications at the time of study).<sup>20</sup>

468

469

‡Of the six studies in high burden countries, three (50%) were conducted in sub-Saharan Africa, two (33%) in Latin America, and one (17%) in East Asia; five (83%) were conducted in upper-middle income countries and one (17%) in a low-income country (per World Bank classifications at the time of study).<sup>20</sup>

470

471

472

§Based on last year of data collection

473

¶Interventions of interest only; several studies implemented more than one intervention of interest

474

||One study estimated incidence of both LTBI and TB disease

475

\*\*Generally reported as a risk or incidence rate

476

HCWs: health care workers; LTBI: latent tuberculosis infection; TB: tuberculosis

477

478 **Table 3. Setting, design, population(s) studied, intervention(s) implemented, and outcome(s) measured in the studies included, divided by high/low TB burden\***  
 479 **countries and listed in reverse chronological order of publication (n = 25)**

| First author,<br>year published     | Setting  | Study<br>design | Population/s  | Intervention/s   |   | Comparator  | Outcome<br>(Metric reported   How<br>measured)  |
|-------------------------------------|--|-----------------|---|--|---|---|---|
|                                     |  |                 |   | Administrative   | Other   |   |   |
| <b>HIGH BURDEN*</b>                 |  |                 |   |  |   |   |   |
| <b>O'Hara, 2017<sup>24</sup></b>    | 28 public hospitals, South Africa                | Cross-sectional | HCWS: all individuals working at study hospitals  | TB infection control audit in 2012; separate score for administrative controls (triage, isolation)   | Scores also for (i) environmental controls; (ii) personal respiratory protection; and (iii) miscellaneous measures, as well as overall score  | Facilities with higher vs. those with lower administrative scores (a higher score equalled more IPC measures in place). | TB disease incidence (Episodes of TB disease per 100,000 HCWs   Ascertained through review and probabilistic matching of HR and TB register)  |
| <b>Claassens, 2013<sup>25</sup></b> | 121 primary health care facilities, South Africa | Cross-sectional | HCWs: all individuals employed at study facilities  | TB infection control audit in May–Sep 2009; separate score for administrative controls   | Scores also for (i) environmental controls and (ii) personal respiratory protection, as well as overall score   | Facilities with higher vs. those with lower administrative scores (a higher score equalled more IPC measures in place). | TB disease incidence, Jan 2006–Dec 2008 (Binary outcome defined as ≥1 TB episode among HCWs in a facility vs. 0 episodes   Ascertained through questionnaire answered by facility manager)  |
| <b>da Costa, 2009<sup>26</sup></b>  | One hospital, Brazil                             | During/after    | HCWs: admin clerks, housekeepers, lab/radiology techs, nurses, physicians, social workers | Isolation of: all patients with sputum sent for AFB +/- mycobacterial culture, patients with productive cough until one smear negative, and HIV+ patients with abnormal CXR; and Education of HCWs | Specialised TB o/p clinic. Use of N95 respirator for all person entering room with isolated patient. Patients leaving room for diagnostic tests wore surgical mask and educated on cough etiquette. | Period after (2002–2003) vs. period during (1998–2001) implementation of IPC measures.†                                 | LTBI incidence (TST conversions per 1000 PM   Annual serial TST, positive defined as ≥10 mm induration, conversion as ≥10 mm induration if initial two-step or ≥15 mm if initial one-step ) |

| First author, year published | Setting                         | Study design    | Population/s  | Intervention/s   |   | Comparator   | Outcome (Metric reported   How measured)  |
|------------------------------|---------------------------------|-----------------|---|--|---|--|---|
|                              |                                 |                 |   | Administrative   | Other   |  |   |
| Roth, 2005 <sup>27</sup>     | Four general hospitals, Brazil  | Cross-sectional | HCWs: administrative workers, auxiliary staff, nurses, and physicians     | Rapid diagnosis, treatment, and isolation.   | Some hospitals had engineering measures (negative pressure isolation rooms with HEPA filtration and 20 ACH; N95 respirator for HCWs and surgical mask for patient until isolated.   | Compared all four hospitals and two hospitals (A & B) with better IPC vs. two hospitals (C & D) with worse IPC measures. | LTBI prevalence and LTBI incidence (Prevalence of positive TST and TST conversions per 1000 PM   Induration ≥10 mm, if <10 mm, TST repeated after 7–10 days)  |
| Yanai, 2003 <sup>28</sup>    | One referral hospital, Thailand | Before/after    | HCWs: no further details provided   | Interventions (SOPs & IPC plan) aimed at: time from admission to initiation of TB treatment; timeliness of suspicion of TB; collection of specimens; reporting results, isolation, & initiation of treatment monitored | Prevention interventions for HCWs & patients; engineering control measures (negative & natural ventilation; in lab, air exhaust and UVGI) and personal respirators (N95 masks encouraged when HCWs exposed to infectious TB patients. Lab staff processing MTB cultures used personal respirators). | Period after (1998–1999) vs. period before (1995–1997) implementation of IPC measures.                                   | LTBI incidence rate and TB disease incidence (TST conversions per 1,000 PY and TB disease incidence per 100 PY   Annual two-step TST screening, positive defined as induration ≥10 mm; CXR, sputum smear and culture for all HCWs with symptoms or signs of active TB, those on treatment entered into HCW-specific register) |
| Harries, 2002 <sup>29</sup>  | 40 hospitals, Malawi            | Before/after    | HCWs: all hospital-based staff with frequent exposure to medical patients | Guidelines on TB IPC (mid-1998), including prioritising those with cough; rapid collection of sputum; frequency of processing specimens; & spatial separation of people with possible PTB                              | Ventilation (windows left open) and masks (worn by TB patients when undergoing surgery)   | Period after (1999) vs. period before (1996) implementation of IPC measures.   | TB disease incidence (Number/proportion of HCWs registered with TB   Consultation of administrative records and interviews with TB officers; details published separately <sup>30</sup> )   |

LOW BURDEN\*

| First author, year published        | Setting                          | Study design | Population/s  | Intervention/s   |  | Comparator   | Outcome (Metric reported   How measured)  |
|-------------------------------------|----------------------------------|--------------|---|--|--|--|---|
|                                     |                                  |              |   | Administrative   | Other  |  |   |
| <b>Welbel, 2009</b> <sup>31</sup>   | One public hospital, USA         | During/after | HCWs: non-clinical and clinical staff, including physicians, nurses, and training medical staff | Creation of respiratory isolation service for proper & prompt isolation of patients; dedicated technician for service, collection of sputum daily. All HIV+ patients with respiratory symptoms placed in isolation. Implemented 1992–1997. | Engineering changes (negative pressure, UV lights); N95 respirators introduced in 1997.  | Period after (1998–2002) vs. period during (1994–1997) implementation of IPC measures.       | LTBI incidence (TST conversions per 100 PY   Institutional 2-step TST programme established per CDC recommendations; positive defined as induration ≥10 mm) |
| <b>Baussano, 2007</b> <sup>32</sup> | Three health units, Italy        | Before/after | HCWs: clerical, nursing, medical, & SW with negative TST and no previous vaccination with BCG   | Implementation of regional guidelines. Administrative: appointment of TB official at each facility; adoption of procedures to assess risk of TB transmission; prompt diagnosis & isolation of potentially infectious TB cases              | Organisational, technical & educational interventions; respiratory protection measures, particularly while performing cough-inducing procedures. | Period after (2002–2004) vs. period before (1998–2000) implementation of IPC measures.       | LTBI incidence (TST conversions per 100 PY, sex & age-adjusted   Positive defined as induration of ≥10 mm after previous negative TST)                      |
| <b>Jones, 2002</b> <sup>33</sup>    | One teaching medical centre, USA | During/after | HCWs: employees of the medical centre (no other details provided)                               | Rule-out negative pathway: (1) initiation of respiratory isolation protocols; (2) direct patient admission/transfer to Special Immunology/Infectious Disease [SI/ID] unit; and (3) immediate patient placement in respiratory isolation    | Isolation rooms designed to provide negative pressure, six air exchanges/hour, and venting of air outside.                                       | Period after (Jan-Jun 1998) vs. period during (1994–1998) the implementation of the pathway. | LTBI incidence (TST conversions   Review of employee health records)  |

| First author, year published         | Setting                             | Study design | Population/s  | Intervention/s  |  | Comparator   | Outcome (Metric reported   How measured)  |
|--------------------------------------|-------------------------------------|--------------|---|---|--|--|---|
|                                      |                                     |              |   | Administrative  | Other  |  |   |
| <b>Moro, 2000</b> <sup>34</sup>      | One HIV ward in one hospital, Italy | Before/after | HIV+ individuals admitted to outbreak ward whose stay overlapped with infectious periods of MDR-TB patients | Strict AFB isolation procedures initiated for all patients with respiratory disease or fever.   | Patients wore surgical masks when being transported for diagnostic purposes. Surgical masks mandatory for persons entering pts rooms.                                | Period after (Jul 1993–Feb 1994) vs. before (Oct–Jun 1993) the implementation of IPC measures. | MDR-TB disease incidence (New cases per 1,000 PD   Case definition: signs, symptoms, and an isolate resistant to at least one first-line drug; medical and microbiology records consulted to ascertain history & drug susceptibility) |
| <b>Bangsberg, 1999</b> <sup>35</sup> | One tertiary referral centre, USA   | During/after | HCWs: medical house staff   | All patients known HIV+, with HIV risk factors, or homelessness presenting with pneumonia/evidence of TB isolated on presentation at ED; admitted to negative-pressure isolation room; and remained in respiratory isolation until three negative AFBs. | Implementation of revised policy in 1992 based on CDC guidelines (published in 1993). Modifications to facility & personal protective equipment.                     | Period after (Dec 1992–Jun 1994) vs. during (Jun 1992) the implementation of IPC measures.     | LTBI incidence (TST conversions per 100 PY   Positive defined as induration of ≥10 mm, conversion as increase of ≥6 mm to a value of at least 10 mm)  |
| <b>Behrman, 1998</b> <sup>36</sup>   | ED in one hospital, USA             | Before/after | HCWs: all employees at study hospital   | New TB control measures in the ED, including four respiratory isolation rooms.  | 100% non-recirculated air in trauma area, improved ventilation, laminar flow of air from registrars to patients, and acrylic plastic droplet shields for registrars. | Period after (1996) vs. period before (Jul 1994–Dec 1995) implementation of IPC measures.      | LTBI incidence (TST conversions   Positive defined as induration of ≥5 mm after 48–72 hours)  |

| First author, year published         | Setting  | Study design    | Population/s  | Intervention/s  |  | Comparator  | Outcome (Metric reported   How measured)  |
|--------------------------------------|--|-----------------|---|---|--|---|---|
|                                      |  |                 |   | Administrative  | Other  |   |   |
| <b>Blumberg, 1998</b> <sup>37</sup>  | One public hospital, USA                           | During/after    | HCWs: staff in a teaching program (50% of their clinical rotations in the hospital)         | Mandatory isolation of all patients with active TB, those with TB from differential diagnosis (or when sputum tests ordered), HIV+ or at high risk of HIV infection. Isolation discontinued after 3 consecutive negative AFBs/patient discharged. | Interim engineering controls (conversion of 90 rooms to negative pressure rooms by addition of window fan); personal respiratory protection equipment (submicron mask used by all HCWs entering respiratory isolation room). | Period after (Jan 1993–Jun 1997) vs. period during (Jul–Dec 1992) implementation of IPC measures. | LTBI incidence (TST conversions per 100 PY   One-step testing; positive defined as induration of ≥10 mm after 48–72 hours)  |
| <b>Louther, 1997</b> <sup>38</sup>   | Urban hospital with a dedicated 'AIDS centre', USA | During/after    | HCWs: All employees at study hospital (excluding those with boosted response to serial TST) | Respiratory isolation of all individuals suspected of having active TB; Triage of people attending ED/OPD and isolation of HIV+ people with particular symptoms (details published separately <sup>39</sup> )                                     | Negative-pressure ventilation rooms<br>Germicidal UV (n = 125 units) in patient rooms, waiting areas, and nursing stations<br>PPE: Technol shield masks, dust-mist-fume respirators, and HEPA respirators                    | Period after (1993–1994) vs. period during (1991–1992) implementation of IPC measures.            | LTBI incidence (Percentage TST conversions   Positive defined as induration ≥10 mm within 2 years of a previous negative result)  |
| <b>Uyamadu, 1997</b> <sup>22</sup>   | One teaching hospital, USA                         | Before/after    | HCWs: all staff at study hospital   | Mandatory respiratory isolation of all patients with community-acquired pneumonia, until two negative AFBs/TB ruled out on clinical grounds   | None   | Period after (1988–Jul 1991) vs. period before (Jul 1991–1994) implementation of isolation        | LTBI incidence (Percentage TST conversion   Positive defined as induration ≥10 mm after 48–72 hours)  |
| <b>Sinkowitz, 1996</b> <sup>40</sup> | 1,494 hospitals, USA                               | Cross-sectional | Bronchoscopists and other HCWs  | Compliance with 1990 CDC TB guideline AFB isolation room (survey conducted in March 1993, 50% response rate).   | All 4 criteria; at least 3 criteria (negative-pressure, exhaust directed outside & single/cohorting of patients); at least negative-pressure criterion; at least the direct outside exhausted air criterion                  | Hospitals implementing all four CDC criteria vs. those not implementing all four criteria         | LTBI incidence (TST conversions measured in 1992, stratified by number of TB patients hospitalised in 1992   Hospitals reported on proportion of HCWs with TST ≥10 mm and previous negative result) |



| First author, year published       | Setting                     | Study design    | Population/s   | Intervention/s  |  | Comparator  | Outcome (Metric reported   How measured)   |
|------------------------------------|-----------------------------|-----------------|--|---|--|---|--|
|                                    |                             |                 |  | Administrative  | Other  |   |  |
| <b>Blumberg, 1995<sup>41</sup></b> | One public hospital, USA    | During/after    | HCWs at the hospital (not those on rotation)                                     | Mandatory isolation of all patients with active TB, those with TB from differential diagnosis (or when sputum tests ordered), HIV+ or at high risk of HIV infection. Isolation discontinued after 3 consecutive negative AFBs/patient discharged.       | Interim engineering controls and personal respiratory protection equipment (per Blumberg, 1998, above).                                      | Period after (Jul 1992–Jun 1994) vs. period during (Jan–Jun 1992) implementation of IPC measures.                         | LTBI incidence (TST conversions   One-step testing; positive defined as induration $\geq 10$ mm after 48–72 hours) |
| <b>Fridkin, 1995<sup>42</sup></b>  | 210 hospitals, USA          | Cross-sectional | HCWs, measured in 1992, among hospitals reporting at least 6 TB patients in 1992 | Compliance with 1990 CDC TB guideline AFB isolation room (survey conducted in March 1993, 50% response rate).<br>1. All 4 criteria no vs. yes (includes single/cohorting of patients);<br>2. $\geq 3$ criteria (includes single/cohorting of patients). | Per Sinkowitz, 1996, above.  | Hospitals implementing all four CDC criteria vs. those not and hospitals implementing $\geq 3$ CDC criteria vs. those not | LTBI incidence (TST conversions   Reported percentage of HCWs who received a TST that became newly positive)       |
| <b>Holzman, 1995<sup>43†</sup></b> | One municipal hospital, USA | Before/after    | Non-physician HCWs: nursing, housekeeping, radiology, and other staff            | Implementation of 1990 CDC guidelines. Triage; early isolation & treatment (drug-susceptibility testing not specified); written criteria for starting/stopping precautions.   | Negative pressure rooms with ventilation, filtration, and UV radiation equivalent to 28 air changes/hour; PPE: dust-mist & HEPA respirators. | Period after (Nov 1993–Oct 1994) vs. period before (Nov 1992–Oct 1993) implementation of IPC measures.                    | LTBI incidence (TST conversions   Not described, cite CDC 1994 guidelines <sup>44</sup> )                          |

| First author, year published | Setting   | Study design | Population/s  | Intervention/s   |  | Comparator   | Outcome (Metric reported   How measured)  |
|------------------------------|---|--------------|---|--|--|--|---|
|                              |   |              |   | Administrative   | Other  |  |   |
| Jarvis, 1995 <sup>45</sup>   | Three hospitals (A[1989–91], B [1989–91] & D [1990–1]), USA | Before/after | HCWs with baseline negative TST result and follow-up TST within 2 years | Implementation of 1990 CDC guidelines, including education of HCWs to increase index of suspicion for TB; prompt collection & processing of specimens; and prompt identification & isolation of pts with known/suspected TB. | Engineering controls (negative pressure isolation rooms & air exhausted outside) and respiratory protective devices (submicron or dust-mist).  | Period after (not defined) vs. period before (not defined) implementation of IPC measures.             | LTBI incidence (TST conversions   Positive defined as induration $\geq 10$ mm if unknown baseline or $\geq 10$ mm increase on baseline induration)  |
| Maloney, 1995 <sup>46</sup>  | One teaching hospital, USA                                  | Before/after | HCWs with documented negative TST in previous 24 months                 | Implementation of 1990 CDC guidelines, including prompt isolation & treatment of patients with TB; rapid diagnosis.  | Negative-pressure isolation rooms; moulded surgical masks for HCWs.  | Period after (Jul 1991–Aug 1992) vs. period before (Jan 1990–Jun 1991) implementation of IPC measures. | LTBI incidence (TST conversions   Positive defined as induration $\geq 10$ mm)  |
| Stroud, 1995 <sup>47</sup>   | One hospital, USA   | Before/after | “AIDS patients” with same ward exposure to MDR-TB pts                   | Aggressive implementation of administrative controls: rapid placement of TB patients or suspected TB patients in single-patient rooms. Expanded TB treatment prescribed.   | In period III, engineering changes (some isolation rooms fitted with UV lights and fans that exhausted air outside) provided $\geq 6$ air exchanges/hour and created negative pressure in hallway. | Period after (Apr 1990–May 1991) vs. period before (Jan 1989–Mar 1990) implementation of IPC measures. | MDR-TB disease risk (“Attack rate”, expressed as %   Case definition: diagnosis of active TB during study period with MTB isolate resistant to at least isoniazid and streptomycin, ascertained through review of hospital and medical records) |
| Wenger, 1995 <sup>48</sup>   | One HIV ward in hospital, USA                               | Before/after | HCWs working on the HIV ward  | Higher index of suspicion for TB, stricter criteria for discontinuing isolation; restriction of cough procedures to isolation rooms; expansion of initial TB treatment to 4 agents; shorter turnaround time for AFB, DST.    | Negative pressure, masks   | Period after (Jun 1990–Jun 1992) vs. period before (Jan–May 1990) implementation of IPC measures.      | LTBI incidence (TST conversions   Positive defined as induration $\geq 10$ mm and $\geq 6$ mm larger than previously reported induration)   |

| First author, year published        | Setting                    | Study design | Population/s  | Intervention/s   |       | Comparator  | Outcome (Metric reported   How measured)  |
|-------------------------------------|----------------------------|--------------|---|--|-------|---|---|
|                                     |                            |              |   | Administrative   | Other |   |   |
| <b>Bryan, 1983</b> <sup>49</sup>    | One teaching hospital, USA | During/after | HCWs (no details provided)  | TB Registry: documents dates/results of AFBs, CXR results, and whether patient is put in respiratory isolation & when; register reviewed weekly by TB epidemiologist | None  | Period after (1977–1981) vs. period during (1976) implementation of IPC measures.             | LTBI incidence (TST conversion rates   One-step testing; no other details provided) |
| <b>Jacobson, 1957</b> <sup>21</sup> | One general hospital, USA  | Before/after | HCWs: hospital employees (before 1952, only physicians, student nurses and TB staff examined regularly) | Routine CXR screening programme for new admissions   | None  | Period after (1952–1955) vs. period before (1942–1951) implementation of screening programme. | TB disease incidence rate (TB cases per 1,000 PY   )                                |

480

\*Based on WHO 2016 definitions<sup>15</sup>

481

†This paper refers to both 1998–2001 and 1999–2001 as the first period of observation; 1998–2001 used for the purposes of this review.

482

‡Conference abstract only

483

↑: increase; ↓: decrease; ACH: air changes per hour; adj.: adjusted; admin: administrative; AFB: acid-fast bacilli; AIDS: acquired immune deficiency syndrome; BCG: bacille

484

Calmette-Guérin; CDC: Centers for Disease Control and Prevention; CI: confidence interval; CXR: chest x-ray; DST: drug sensitivity testing; ED: emergency department; HCWs: health

485

care workers; HEPA: high efficiency particulate air; HIV+: HIV-positive; HR: human resources; IPC: infection prevention and control; lab: laboratory; MDR: multidrug-resistant; MTB:

486

*Mycobacterium tuberculosis*; mth: month; o/p: outpatient; OR: odds ratio; PD: person-day; PM: person-month; pt: patient; PY: person-years; SOP: standard operating procedure;

487

SW: social worker; TB: tuberculosis; tech: technician; TST: tuberculin skin test; unadj.: unadjusted; USA: United States of America; UV: ultraviolet; UVGI: ultraviolet germicidal

488

irradiation

489

Table 4. Main findings of included studies divided by high/low TB burden\* countries and listed in reverse chronological order of publication (n = 25)

| First author, year published, [ref] | Country      | Intervention/s   |                   |    |                  | Outcome/s   Population/s   | Primary findings   |  |  | Other findings   |
|-------------------------------------|--------------|------------------|-------------------|----|------------------|----------------------------|--|--|--|--|
|                                     |              | Tri <sup>g</sup> | Isol <sup>n</sup> | Tx | Oth <sup>†</sup> |                            | No intervention  | Intervention   | Effect estimate  |  |
| <b>HIGH BURDEN</b>                  |              |                  |                   |    |                  |                            |  |  |  |  |
| <b>O'Hara, 2017<sup>24</sup></b>    | South Africa | Yes              | Yes               | No | Yes              | TB disease   HCWs          | Not reported   | Not reported   | Unadj. OR for higher vs. lower administrative score 0.94 (95% CI 0.87–1.02), <i>p</i> = 0.12<br>Adj. OR for higher vs. lower administrative score 0.97 (95% CI 0.90–1.04), <i>p</i> = 0.36 | <ul style="list-style-type: none"> <li>• Median administrative score 21 (IQR 18–24, range 15–28); max possible score 32</li> <li>• Adj. OR adjusted for environmental score, PPE score, miscellaneous score, and number of TB patients</li> </ul>  |
| <b>Claassens, 2013<sup>25</sup></b> | South Africa | No               | Yes               | No | Yes              | TB disease   HCWs          | Not reported   | Not reported   | Unadj. OR for higher vs. lower administrative score (continuous): 1.09 (95% CI 0.99–1.19), <i>p</i> = 0.07   | <ul style="list-style-type: none"> <li>• Administrative score: range from –4 to 19, mean 8 (SD 4). Administrative score not included in adjusted model</li> <li>• ORs also shown for total, environmental controls, and personal respiratory protection scores</li> </ul>  |
| <b>da Costa, 2009<sup>26</sup></b>  | Brazil       | No               | Yes               | No | Yes              | TST conversion rate   HCWs | <b>1998–2001:</b><br>5.8 (95% CI 4.9–6.7) per 1,000 PM (25 events in 4,307 PM) | <b>2002–2003:</b><br>3.7 (95% CI 2.8–4.6) per 1,000 PM (15 events in 3,858 PM) | Hazard ratio = 0.46 (95% CI 0.23–0.89), <i>p</i> = 0.006   | <ul style="list-style-type: none"> <li>• Adjusted hazard ratio 0.24 (95% CI 0.10–0.54), adjusted for exposure to person with PTB in hospital &amp; occupation.</li> <li>• Fidelity: reduced time between microscopy request and result between two time-periods</li> <li>• Increased proportion of PTB diagnosed among suspected cases isolated</li> </ul> |

| First author, year published, [ref] | Country  | Intervention/s   |                   |    |                  | Outcome/s   Population/s                                 | Primary findings   |   |   | Other findings  |
|-------------------------------------|----------|------------------|-------------------|----|------------------|--|--|---|---|---|
|                                     |          | Tri <sup>g</sup> | Isol <sup>n</sup> | Tx | Oth <sup>†</sup> |  | No intervention  | Intervention  | Effect estimate   |   |
| Roth, 2005 <sup>27</sup>            | Brazil   | Yes              | Yes               | No | Yes              | TST prevalence   HCWs<br><br>TST conversion rate   HCWs  | <b>TST prevalence:</b><br><b>Hosp C:</b> 65.8% (574/872); <b>Hosp D:</b> 62.2% (454/730)<br><br><b>TST conversion:</b><br><b>Hosp C:</b> 19.8/1,000 PM (n = 34); <b>Hosp D:</b> 12.2/1,000 PM (n = 21) | <b>TST prevalence:</b><br><b>Hosp A:</b> 46.7% (407/872); <b>Hosp B:</b> 69.6% (1,353/1,945)<br><br><b>TST conversion:</b><br><b>Hosp A:</b> 7.4/1,000 PM (n = 19); <b>Hosp B:</b> 8.1/1,000 PM (n = 31)  | Hospital C & D, 16.0/1,000 PM vs. A & B, 7.8/1,000 PM; <i>p</i> <0.001. Hospitals B, C, and D vs. A: unadj. OR 1.3, 3.2, and 3.4, respectively; adj. OR (95% CI; <i>p</i> -value) 1.0 (0.5–1.8; NS), 2.3 (1.2–4.2; 0.01), 2.8 (1.4–5.6; 0.002), respectively. | <ul style="list-style-type: none"> <li>Reported annual number of new PTB cases: Hosp A 200–250; Hosp B 100–150; Hosp C 450–500; and Hosp D 50–60</li> </ul>   |
| Yanai, 2003 <sup>28</sup>           | Thailand | Yes              | Yes               | No | Yes              | TST conversion rate   HCWs<br><br>TB disease rate   HCWs | <b>TST conversion 1995–1997:</b> 9.3 (95% CI 3.3–15.3) per 100 PY<br><br><b>TB disease 1995–1997:</b> 0.65 (29/4,464) per 100 PY   | <b>TST conversion 1998:</b> 6.4 (95% CI 1.5–11.4) per 100 PY; <b>1999:</b> 2.2 (95% CI 0–5.1) per 100 PY<br><br><b>TB disease 1998:</b> 0.42 (7/1,654) per 100 PY; <b>1999:</b> 0.44 (7/1,583) per 100 PY | <b>TST conversion Rate ratio (vs. 1995–1997)</b><br><b>1998:</b> unadj. 0.9 (0.4–2.2); adj. 0.4 (0.1–1.6), <i>p</i> = 0.2.<br><b>1999:</b> unadj. 0.03 (0.01–0.2); adj. 0.01 (0–0.04), <i>p</i> <0.001<br><br><b>TB disease</b><br>No rate ratio reported     | <ul style="list-style-type: none"> <li>Intervention implemented in 1996. Increase in numbers of smear-positive TB patients identified 1990 (102) to 1999 (356)</li> <li>Numerators &amp; denominators unclear</li> <li>Active TB disease incidence among HCWs also reported for the period 1988–1994</li> </ul> |
| Harries, 2002 <sup>29</sup>         | Malawi   | Yes              | Yes               | No | Yes              | TB disease   HCWs  | <b>1996:</b> 3.7% (100/2,697)  | <b>1999:</b> 3.2% (96/2,979)  | Reported as "non-significant"   | <ul style="list-style-type: none"> <li>Fidelity (Jan–Jun 1998 vs. Jan–Jun 1999): similar length of time from admission to diagnosis and treatment</li> </ul>  |
| <b>LOW BURDEN</b>                   |          |                  |                   |    |                  |  |  |   |   |   |

| First author, year published, [ref] | Country | Intervention/s   |                   |     |                  | Outcome/s   Population/s                         | Primary findings   |   |   | Other findings   |
|-------------------------------------|---------|------------------|-------------------|-----|------------------|--|--|---|---|--|
|                                     |         | Tri <sup>g</sup> | Isol <sup>n</sup> | Tx  | Oth <sup>†</sup> |  | No intervention  | Intervention  | Effect estimate   |  |
| Welbel, 2009 <sup>31</sup>          | USA     | Yes              | Yes               | Yes | Yes              | TST conversion rate   HCWs                       | <b>1994:</b> 4.22/100 PY<br><b>1995:</b> 2.92/100 PY;<br><b>1996:</b> 1.41/100 PY;<br><b>1997:</b> 1.48/100 PY | <b>1998:</b> 0.74/100 PY;<br><b>1999:</b> 0.57/100 PY;<br><b>2000:</b> 1.04/100 PY;<br><b>2001:</b> 0.71/100 PY;<br><b>2002:</b> 0.28/100 PY                                | <b>2002 vs. 1994:</b> $p < 0.001$<br>1997 vs. 1994: $p < 0.001$<br>2002 vs. 1997: $p = 0.14$          | <ul style="list-style-type: none"> <li>Number of inpatients with active TB declining from 1997 onwards</li> </ul>  |
| Baussano, 2007 <sup>32</sup>        | Italy   | Yes              | Yes               | No  | Yes              | TST conversion rate   HCWs                       | <b>Jan 1998–Jun 2000:</b> 2.19 (95% CI 1.81–2.56) per 100 PY (106 events in 4,034 PY)                          | <b>Jan 2002–Dec 2004:</b> 0.84 (95% CI 0.55–1.28) per 100 PY (42 events in 4,463 PY)  | Not reported.   | <ul style="list-style-type: none"> <li>Events per PY includes data to Dec 2001.</li> <li>Data also shown by occupation (work activity) &amp; workplace</li> </ul>  |
| Jones, 2002 <sup>33</sup>           | USA     | No               | Yes               | No  | Yes              | TST conversion   HCWs                            |  | <b>Overall (1995–1998):</b> 2.3% (92/~4000);<br><b>In SI/ID unit</b><br><b>Jan 1994–Jan 1998:</b> 0% (0/60);<br><b>Feb–Jun 1998:</b> 3.33% (2/60)                           | Not reported  | <ul style="list-style-type: none"> <li>Fidelity: 50 patients placed on pathway from 1995–1998</li> </ul>   |
| Moro, 2000 <sup>34</sup>            | Italy   | Yes              | Yes               | No  | Yes              | MDR-TB incidence rate   HIV-positive in-patients | <b>Oct–Jun 1993:</b> 10.6/1,000 PD (26 events in 2,455 PD; 90 individuals exposed)                             | <b>Jul 1993–Feb 1994:</b> 0/1,000 PD (0 events in 654 PD; 44 individuals exposed)   | Not reported.   | <ul style="list-style-type: none"> <li>37 patients exposed in both before and after period: 0/1,839 MDR-TB episodes</li> <li>Over the entire time period there were several infectious MDR-TB cases in the ward</li> </ul>           |
| Bangsberg, 1999 <sup>35</sup>       | USA     | No               | Yes               | No  | Yes              | TST conversion rate   HCWs                       | <b>Jun 1992:</b> 5.8/100 PY (9/88 [10.3%])   | <b>Dec 1992:</b> 5.1/100 PY (2/77 [2.6%]);<br><b>Jun 1993:</b> 0/100 PY (0/88 [0%]);<br><b>Dec 1993:</b> 2.3/100 PY (1/93 [1.1%]);<br><b>Jun 1994:</b> 0/100 PY (0/86 [0%]) | Not reported overall. Data also reported for interns showing a decline over 1992–1994 ( $p = 0.029$ ) | <ul style="list-style-type: none"> <li>Fidelity: proportion properly isolated increased from 38% (Jan–Jun 1992) to 75% (Jul–Dec 1993)</li> <li>Participation of house staff ranged from 77% to 88% in the years reported.</li> </ul> |

| First author, year published, [ref] | Country | Intervention/s   |                   |    |                  | Outcome/s   Population/s   | Primary findings  |   |  | Other findings   |
|-------------------------------------|---------|------------------|-------------------|----|------------------|----------------------------|---|---|--|--|
|                                     |         | Tri <sup>g</sup> | Isol <sup>n</sup> | Tx | Oth <sup>†</sup> |                            | No intervention   | Intervention  | Effect estimate  |  |
| Behrman, 1998 <sup>36</sup>         | USA     | Yes              | Yes               | No | Yes              | TST conversion   HCWs      | <b>Jul 1994–Dec 1995 (cycle 2)</b><br>ED staff: 12.0% (6/50)<br>Other hospital employees: 2.1% (51/2,514)   | <b>1996 (cycle 3)</b><br>ED staff: 0% (0/64)<br>Other hospital employees: 1.2% (36/3,000)   | Not reported   | <ul style="list-style-type: none"> <li>No change in the number of culture-positive admissions from 1993–1996. No data reported on frequency of use of respiratory isolation rooms.</li> <li>No data on TST conversions from Mar 1993–Dec 1994 (cycle 1).</li> </ul>            |
| Blumberg, 1998 <sup>37</sup>        | USA     | Yes              | Yes               | No | Yes              | TST conversion rate   HCWs | <b>Jul–Dec 1992:</b><br>5.98/100 PY (21 conversions)  | <b>Jan 1993–Jun 1997:</b><br>1.09/100 PY (31 conversions)   | Not reported, but reported a p-value comparing the two time-periods: <0.001  | <ul style="list-style-type: none"> <li>Also showed data separately for US medical school graduate staff during and after implementation (5.26 vs. 0.72/100 PY, <math>p &lt; 0.001</math>; 17 and 19 conversions, respectively)</li> </ul>                                      |
| Louther, 1997 <sup>38</sup>         | USA     | Yes              | Yes               | No | Yes              | TST conversion   HCWs      | <b>1991–1992</b><br><b>Overall 7.2 conversions per 100 PY (65 events in 898 PY)</b><br>Lab workers 6.3 (3/48);<br>Physicians/nurses 7.2 (26/363); Social service 8.1 (9/111);<br>Housekeeping 11.7 (21/179);<br>Finance 3.0 (6/197) | <b>1993–1994</b><br><b>Overall 3.3 conversions per 100 PY (32 events in 971 PY)</b><br>Lab workers 2.3 (1/44);<br>Physicians/nurses 3.0 (12/398); Social service 2.2 (3/139);<br>Housekeeping 6.7 (12/179); Finance 1.9 (4/211) | <b>Overall crude rate ratio 0.46†; <math>p = 0.001</math></b><br>Lab workers 0.37, $p = 0.42$ ; Physicians/nurses 0.42, $p = 0.01$ ; Social service 0.27, $p = 0.04$ ;<br>Housekeeping 0.57, $p = 0.12$ ; Finance 0.63, $p = 0.48$ | <ul style="list-style-type: none"> <li>Number of new cases of TB per year ranged from 56 to 118 over study period</li> <li>Isolation days per year ranged from 6,360 to 10,883 over study period</li> <li>Information on TST available for &gt;90% of all employees</li> </ul> |

| First author, year published, [ref] | Country | Intervention/s   |                   |    |                  | Outcome/s   Population/s        | Primary findings   |   |   | Other findings   |
|-------------------------------------|---------|------------------|-------------------|----|------------------|---------------------------------|--|---|---|--|
|                                     |         | Tri <sup>g</sup> | Isol <sup>n</sup> | Tx | Oth <sup>†</sup> |                                 | No intervention  | Intervention  | Effect estimate   |  |
| Uyamadu, 1997 <sup>22</sup>         | USA     | No               | Yes               | No | No               | TST conversion   HCWs           | <b>1988–1990:</b> overall 0.6% (23/3,842);<br><b>Jan–Jul 1991:</b> 1.7% (13/768).  | <b>Jul 1991–Dec 1994:</b> average 0.6%<br><b>Jul–Dec 1991:</b> 1.3% (10/774)<br><b>1992:</b> 0.5% (9/1,637)<br><b>1993:</b> 0.7% (9/1,325)<br><b>1994:</b> 0.6% (8/1,381) | Not reported.   | <ul style="list-style-type: none"> <li>Fidelity: 100% compliance with respiratory isolation</li> <li>Number of new TB cases in hospital remained stable from 1991–1994</li> </ul>  |
| Sinkowitz, 1996 <sup>40</sup>       | USA     | No               | Yes               | No | Yes              | TST conversion   Bronchoscopies | <b>All 4 criteria - no: Bronchoscopists</b><br>No TB pts: 0% (n = 16);<br>1-5 TB pts: 8.0% (n = 22);<br>≥6 TB pts: 5.1% (n = 11) | <b>All 4 criteria - yes: Bronchoscopists</b><br>No TB pts: 3.3% (n = 13);<br>1-5 TB pts: 8.3% (n = 39);<br>≥6 TB pts: 5.7% (n = 16)                                       | Not reported.   | <ul style="list-style-type: none"> <li>Results also reported for negative-pressure, air exhaust, &amp; respiratory protection criterion</li> </ul>   |
|                                     |         |                  |                   |    |                  | TST conversion   HCWs           | <b>HCWs</b><br>No TB pts: 0.49% (n = 127);<br>1-5 TB pts: 0.64% (n = 116);<br>≥6 TB pts 0.76% (n = 34)                           | <b>HCWs</b><br>No TB pts: 0.53% (n = 75);<br>1-5 TB pts: 0.69% (n = 185);<br>≥6 TB pts 0.90% (n = 66)   |   |  |
| Blumberg, 1995 <sup>41</sup>        | USA     | Yes              | Yes               | No | Yes              | TST conversion   HCWs           | <b>Jan–Jun 1992:</b> 3.3% (118/3,579)  | <b>Jul–Dec 1992:</b> 1.7% (51/2,975);<br><b>Jan–Jun 1993:</b> 1.4% (67/4,715);<br><b>Jul–Dec 1993:</b> 0.6% (30/4,775);<br><b>Jan–Jun 1994:</b> 0.4% (23/5,153)           | Not reported.<br>Reported p-value comparing the five time-periods: <0.001 | <ul style="list-style-type: none"> <li>Fidelity to the intervention: Jul 1991–Feb 1992 (8 mths) 4.4 TB exposure episodes/mth (35/103 not appropriately isolated) vs. Mar 1992–Jun 1994 (28 mths) 0.6 TB exposure episodes/mth (18/358 not appropriately isolated)</li> </ul> |



| First author, year published, [ref] | Country | Intervention/s   |                   |     |                  | Outcome/s   Population/s | Primary findings   |   |   | Other findings  |
|-------------------------------------|---------|------------------|-------------------|-----|------------------|--------------------------|--|---|---|---|
|                                     |         | Tri <sup>g</sup> | Isol <sup>n</sup> | Tx  | Oth <sup>†</sup> |                          | No intervention  | Intervention  | Effect estimate   |   |
| Fridkin, 1995 <sup>42</sup>         | USA     | No               | Yes               | No  | Yes              | TST conversion   HCWs    | <b>All 4 criteria - No:</b> 1.89% (383/20,296; 17 hospitals).<br><b>≥3 criteria - No:</b> 1.83% (380/20,776; 16 hospitals).  | <b>All 4 criteria - Yes:</b> 0.60% (348/57,600; 28 hospitals).<br><b>≥3 criteria - Yes:</b> 0.62% (376/60,371; 30 hospitals).                                       | <b>All 4 criteria: Yes vs. No:</b> $p = 0.02$ ;<br><b>≥3 criteria: Yes vs. No:</b> $p = 0.03$   | <ul style="list-style-type: none"> <li>• Similar trend for at least negative-pressure or at least the direct outside exhausted air criterion</li> <li>• Also restricted analysis to high risk HCWs (includes bronchoscopists &amp; respiratory therapists) and found similar results</li> </ul> |
| Holzman, 1995 <sup>43</sup><br>§    | USA     | Yes              | Yes               | No  | Yes              | TST conversion   HCWs    | <b>Nov 1992–Oct 1993:</b><br><b>Overall 90/2,132 (4.2%);</b><br>Nursing 54/608 (8.9);<br>Housekeeping 9/105 (8.6);<br>Radiology 2/50 (4.0);<br>Misc./Unk. 14/474 (3.0) | <b>Nov 1993–Oct 1994</b><br><b>Overall 23/1,995 (1.2%);</b><br>Nursing 11/519 (2.1);<br>Housekeeping 3/90 (3.3);<br>Radiology 1/74 (1.4);<br>Misc./Unk. 1/573 (0.2) | <b>Percentage reduction (95% CI), p-value</b><br><b>Overall 73% (57–43), <math>p &lt; 0.001</math>;</b><br>Nursing 76% (44–90), $p < 0.001$ ;<br>Housekeeping 61% (0–89);<br>Radiology 66% (0–97);<br>Misc./Unk. 94% (55–99), $p < 0.001$ |   |
| Jarvis, 1995 <sup>45</sup>          | USA     | No               | Yes               | Yes | Yes              | TST conversion   HCWs    | <b>Baseline period (not defined):</b><br><b>A:</b> 24% (7/29);<br><b>B:</b> 9% (2/22);<br><b>D:</b> 12% (15/123)   | <b>Intervention period (not defined)</b><br><b>A:</b> 0% (0/23);<br><b>B:</b> 18% (6/33);<br><b>D:</b> 3% (5/150)   | <b>A:</b> $p = 0.01$ ;<br><b>B:</b> $p = NS$ ;<br><b>D:</b> $p = 0.01$  | <ul style="list-style-type: none"> <li>• Fidelity: proportion of patients on ward with same-ward exposures decreased in intervention (15%) vs. baseline period (74%). Decreased in all hospitals</li> <li>• In hospital B there was incomplete implementation of CDC guidelines</li> </ul>      |

| First author, year published, [ref] | Country | Intervention/s   |                   |     |                  | Outcome/s   Population/s    | Primary findings  |   |  | Other findings   |
|-------------------------------------|---------|------------------|-------------------|-----|------------------|-----------------------------|---|---|--|--|
|                                     |         | Tri <sup>g</sup> | Isol <sup>n</sup> | Tx  | Oth <sup>†</sup> |                             | No intervention   | Intervention  | Effect estimate  |  |
| Maloney, 1995 <sup>46</sup>         | USA     | No               | Yes               | Yes | Yes              | TST conversion   HCWs       | <b>Jan 1990–Jun 1991</b><br><b>Overall:</b> 3.1% (26/840)<br><b>Wards housing TB patients:</b> 16.7% (15/90);<br><b>Other wards:</b> 2.8% (7/254) | <b>Jul 1991–Aug 1992</b><br><b>Overall:</b> 3.0% (22/727)<br><b>Wards housing TB patients:</b> 5.1% (4/78);<br><b>Other wards:</b> 4.0% (9/228) | <b>Overall:</b> $p = 0.9$<br><b>Wards housing TB patients:</b> relative risk = 3.2, $p = 0.02$ ;<br><b>Other wards:</b> relative risk = 0.7, $p = 0.5$ | <ul style="list-style-type: none"> <li>TST conversion data also reported subgroup direct/no direct patient contact</li> <li>Fidelity: AFB isolation before 40% vs. after 90%; receiving adequate treatment before 43% vs. after 90%</li> </ul>   |
| Stroud, 1995 <sup>47</sup>          | USA     | Yes              | Yes               | Yes | Yes              | MDR-TB risk   AIDS patients | <b>Jan 1989–Mar 1990</b><br>(period 1): 8.8% (19/216)   | <b>Apr 1990–May 1991</b><br>(period 2): 2.6% (5/193)  | $p = 0.01$   | <ul style="list-style-type: none"> <li>Period 1, n = 16 patients with MDR-TB; Period 2, n = 22 patients with MDR-TB</li> <li>MDR-TB risk was 4.8% (4/84) for those with exposures to periods 1 and 2; and 0.5% (4/863) for AIDS patients without same-ward exposure</li> </ul>   |
| Wenger, 1995 <sup>48</sup>          | USA     | Yes              | Yes               | Yes | Yes              | TST conversion   HCWs       | <b>Jan–May 1990:</b> 28% (7/25)   | <b>Jun 1990–Feb 1991</b><br>[early]: 18% (3/17);<br><b>Mar 1991–Jun 1992</b><br>[late]: 0% (0/23)   | Chi-square for trend (3 time-periods), $p < 0.01$  | <ul style="list-style-type: none"> <li>Stringent isolation criteria were only put into effect in Feb 1991</li> </ul>   |
| Bryan, 1983 <sup>49</sup>           | USA     | No               | Yes               | No  | Yes              | TST conversion   HCWs       | <b>1976:</b> 4.5%   | <b>1977:</b> 5.1%;<br><b>1979:</b> 1.5%;<br><b>1980:</b> 0.85%;<br><b>1981:</b> 0.59%   |  | <ul style="list-style-type: none"> <li>Possible problem of faulty performance of test/ presence of booster phenomenon in 1976–1977</li> <li>n/N not reported</li> <li>Fidelity of intervention (proportion of patients with culture confirmed TB who were isolated): 1976: 3/15; 1977: 9/24; 1978: 8/23; 1979: 18/30; 1980: 14/26</li> </ul> |

| First author, year published, [ref] | Country | Intervention/s   |                   |    |                  | Outcome/s   Population/s         | Primary findings   |   |                 | Other findings   |
|-------------------------------------|---------|------------------|-------------------|----|------------------|----------------------------------|--|---|-----------------|--|
|                                     |         | Tri <sup>‡</sup> | Isol <sup>§</sup> | Tx | Oth <sup>†</sup> |                                  | No intervention  | Intervention  | Effect estimate |  |
| Jacobson, 1957 <sup>21</sup>        | USA     | Yes              | No                | No | No               | TB disease incidence rate   HCWs | <b>1942–1951 (overall time period):</b> 2.0/1,000 PY (78 events in 38,331 PY); | <b>1952-1953:</b> 1.0/1,000 PY (9 events in 9,030 PY);<br><b>1954–1955:</b> 0.3/1,000 PY (3 events in 9,199 PY) | Not reported.   | <ul style="list-style-type: none"> <li>• Peak in 1948–1950 coincided with community wide case-finding activities</li> <li>• Also showed data by HCWs occupation</li> </ul> |

491

\*Based on WHO 2016 definitions<sup>15</sup>

492

†Includes administrative, personal protective, and environmental IPC measures

493

‡Rate ratios derived from data presented and not included in authors' analysis

494

§Conference abstract only

495

adj.: adjusted; AFB: acid-fast bacilli; AIDS: acquired immune deficiency syndrome; CDC: Centers for Disease Control and Prevention; CI: confidence interval; HCWs: health care

496

worker; Isol<sup>§</sup>: isolation or spatial separation; IPC: infection prevention and control; LTBI: latent TB infection; MDR: multidrug-resistant; misc.: miscellaneous; mth: month; OR: odds

497

ratio; Oth: other; PD: person-days; PM: person-months; PPE: personal protective equipment; pt: patient; PY: person-years; ref: reference; SD: standard deviation; SI/ID: Special

498

Immunology/Infectious Disease; TB: tuberculosis; Tri<sup>‡</sup>: triage of people with signs or symptoms of TB; TST: tuberculin skin test; Tx: effective treatment based on drug susceptibility;

499

unadj.: unadjusted; unk.: unknown; USA: United States of America; Y: Yes

500

**Table 5. Summary of quality assessments for retrospective studies\* (n = 18 studies)**

| First author | Year | Reporting<br>(max = 11) | External validity<br>(max = 3) | Internal validity:<br>bias<br>(max = 7) | Internal validity:<br>confounding<br>(max = 6) | Total, n (%/27) |
|--------------|------|-------------------------|--------------------------------|---|--|-----------------|
| Bangsberg    | 1999 | 5                       | 2                              | 4                                       | 1  | 12 (44.4)       |
| Blumberg     | 1995 | 6                       | 2                              | 4                                       | 1  | 13 (48.2)       |
| Blumberg     | 1997 | 6                       | 2                              | 4                                       | 1  | 13 (48.2)       |
| Bryan        | 1983 | 3                       | 1                              | 1                                       | 1  | 6 (22.2)        |
| Claassens    | 2013 | 6                       | 1                              | 2                                       | 2  | 11 (40.7)       |
| Fridkin      | 1995 | 4                       | 0                              | 2                                       | 1  | 7 (25.9)        |
| Harries      | 2002 | 7                       | 1                              | 4                                       | 1  | 13 (48.1)       |
| Holzman      | 1995 | 4                       | 2                              | 2                                       | 2  | 10 (37.0)       |
| Jacobson     | 1957 | 4                       | 0                              | 3                                       | 2  | 9 (33.3)        |
| Jarvis       | 1995 | 6                       | 1                              | 4                                       | 2  | 13 (48.1)       |
| Jones        | 2002 | 3                       | 1                              | 2                                       | 2  | 8 (29.6)        |
| Louther      | 1997 | 3                       | 2                              | 2                                       | 2  | 9 (33.3)        |
| Maloney      | 1995 | 5                       | 2                              | 2                                       | 1  | 10 (37.0)       |
| O'Hara       | 2017 | 7                       | 1                              | 1                                       | 3  | 12 (44.4)       |
| Sinkowitz    | 1996 | 6                       | 0                              | 4                                       | 2  | 12 (44.4)       |
| Stroud       | 1995 | 4                       | 0                              | 2                                       | 1  | 7 (25.9)        |
| Uyamadu      | 1997 | 3                       | 0                              | 2                                       | 1  | 6 (22.2)        |
| Welbel       | 2009 | 5                       | 0                              | 3                                       | 1  | 9 (33.3)        |

501

\*Assessed using the Downs & Black tool<sup>16</sup>

502

503 **Table 6. Summary of quality assessment for prospective studies\* (n = 7 studies)**

| First author | Year | Sequence generation | Allocation concealment | Blinding | Incomplete outcome data | Selective outcome reporting | Other sources of bias |
|--------------|------|---------------------|------------------------|----------|-------------------------|-----------------------------|-----------------------|
| Baussano     | 2007 | No                  | No                     | No       | Yes                     | No                          | No                    |
| Behrman      | 1998 | No                  | No                     | No       | No                      | No                          | No                    |
| da Costa     | 2009 | No                  | No                     | No       | No                      | No                          | No                    |
| Moro         | 2000 | No                  | No                     | No       | No                      | Yes                         | No                    |
| Roth         | 2005 | No                  | No                     | No       | No                      | Yes                         | No                    |
| Wenger       | 1995 | No                  | No                     | No       | No                      | No                          | No                    |
| Yanai        | 2003 | No                  | No                     | No       | No                      | Yes                         | No                    |

504 \* Assessed using the Cochrane collaboration tool for experimental studies and prospective cohort studies  
 505 (<http://www.cochrane-handbook.org>)

506 **Figure 1. PRISMA flow diagram showing databases searched; numbers of records identified, sifted, reviewed, and included; and reasons for exclusion**

507

508 \*References and citations were checked for 25 primary research articles, 19 systematic reviews, and six guidelines (see Supplementary table 3)

509 PRISMA: preferred reporting items for systematic reviews and meta-analyses; Refs: references; SR: systematic review; WoS: Web of Science

510 **Figure 2. Venn diagrams showing overlap between interventions implemented in the 25 studies included**

511

512 Panel A: overlap between the three interventions of interest; Panel B: overlap between the three interventions of  
513 interest and other IPC measures implemented

514 \*Includes administrative, personal protective, and environmental IPC measures

515 IPC: infection prevention and control

516 Figure developed using Venny v2.1,<sup>23</sup> Inkscape (<https://inkscape.org/>), and GIMP (<https://www.gimp.org/>) software.

517